ReviewBiosensors2026
Microfluidic Single-Cell Bioanalysis for Decoding Tumor Heterogeneity.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tumor heterogeneity drives cancer progression, dissemination, therapeutic adaptation, and relapse, yet many clinically relevant cell states are rare, transient, context-dependent, and obscured by population-averaged analysis. This review examines how microfluidic platforms preserve biologically meaningful linkages among cell identity, molecular state, secreted output, functional phenotype, perturbation history, and microenvironmental context, which are frequently disrupted by conventional workflows. We first define analytical requirements imposed by tumor heterogeneity, then examine microwell- and microchamber-based systems, droplet microfluidic platforms, valve-assisted and other active manipulation or capture systems, and integrated multimodal workflows that preserve single-cell information while introducing distinct engineering trade-offs. We further discuss major readout modalities, including genomic and transcriptomic profiling, extracellular vesicle and secretome analysis, metabolic measurements, and proteomic readouts, and applications in circulating tumor-cell dissemination, tumor-microenvironment interactions, and therapy-response heterogeneity. Finally, we highlight bottlenecks in measurement fidelity, source attribution, reproducibility, benchmarking, biological representation, multimodal integration, and clinical validation. We propose that microfluidic single-cell oncology should advance from descriptive profiling toward decision-oriented systems that preserve cell-resolved states, source-attributed outputs, perturbation histories, and longitudinal responses within reproducible workflows and connect them to clinically actionable information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.